This whitepaper looks at different approaches that support accelerated clinical development, manufacture and ultimately approval, including:
- Peptides, a unique class of compounds
- Safety and delivery of oligonucleotides
- FDA and EMA guidelines
- mRNAs: towards the future of protein replacement therapy
To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.
ABOUT THE AUTHOR: Catarina Carrão, biochemist by degree, worked as a biomedical researcher at Max F. Perutz Laboratories, Yale Cardiovascular Center at Yale University School of Medicine, and the Center Cardiovascular Research (CCR) at Charité Medical University.
Have any questions or interested in sponsoring future content? Email email@example.com.